• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

dwesterman@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

A/Prof David Westerman

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

274 Scholarly works
4 Projects

HIGHLIGHTS

  • 2024

    Research grants (ARC, NHMRC, MRFF)

    ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)
  • 2022

    Journal article

    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
    DOI: 10.1182/blood.2021012775
  • 2021

    Journal article

    Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
    DOI: 10.1182/bloodadvances.2021005083
  • 2021

    Research contracts (non-grants)

    Wilson Centre for Lymphoma Genomics
  • 2020

    Journal article

    BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
    DOI: 10.1182/blood-2020-137775
  • 2020

    Journal article

    Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
    DOI: 10.1182/BLOOD.2019004205
  • 2017

    Research Contracts

    Christine and Bruce Wilson Centre for Lymphoma Genomics
David Westerman

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Effect of first-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) on minimal residual disease (uMRD) rates, including in patients with del(17p)/TP53.
    DOI: 10.1200/jco.2026.44.16_suppl.7043
  • 2026

    Journal article

    Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
    DOI: 10.1182/blood.2025032307
  • 2026

    Journal article

    Response to Comment on: "Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel".
    DOI: 10.3324/haematol.2026.300980
  • 2026

    Journal article

    Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
    DOI: 10.1182/bloodadvances.2025016646
  • 2026

    Journal article

    Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions
    DOI: 10.1111/imj.70336
  • 2026

    Journal article

    KRAS internal tandem duplications and alternative driver variants in BRAF Val600Glu negative hairy cell leukemia
    DOI: 10.1080/10428194.2026.2615055
  • 2026

    Journal article

    Detecting T-cell clones of uncertain significance using anti-TRBC1-based flow cytometry
    DOI: 10.1016/j.pathol.2026.03.006
  • 2025

    Journal article

    Landscape of TP53 abnormalities and IGHV mutational profile in untreated Australian patients with chronic lymphocytic leukaemia
    DOI: 10.1016/j.pathol.2025.06.013

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224